What is the Buying Price of Marksans Pharma Share?

The Buying Price of Marksans Pharma share is 233.37 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

How to buy Marksans Pharma Share at Choice?

To buy Marksans Pharma stocks , log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Marksans Pharma, choose your preferred order type, and place the trade.

What is the PE ratio of Marksans Pharma Shares?

The Price-to-earnings (P/E) ratio of Marksans Pharma shares is 26.28. You can compare it with the sector average for relative valuation.

What is the PB ratio of Marksans Pharma Shares?

The Price to Book (P/B) ratio Marksans Pharma shares is 3.63. Useful to assess the stock's value relative to its book value.

Is Marksans Pharma Overvalued?

To assess Marksans Pharma’s valuation compare Sector P/E, P/B which are 68.86 & 2.96 with sector averages, along with growth rates and financial metrics.

What is the Market Cap of Marksans Pharma?

The Market Cap of Marksans Pharma is 10839.94 CR. It indicates the company's size category and trading liquidity.

What is the 52 Week High and Low of Marksans Pharma Share Price?

The 52 week high and low prices of Marksans Pharma share price is 270.7 & 155. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Which sector does Marksans Pharma belong to?

Marksans Pharma belongs to the Healthcare sector.

Marksans Pharma Share price

MARKSANS

Healthcare Large Cap

233.37

5.77 (-2.41%)

NSE

BSE

Last updated on 5 Jun, 2026 | 11:47 IST

BuySell

Today's High

244.42

Today's Low

230.50

52 Week Low

155.00

52 Week High

270.70

Marksans Pharma Chart

ChartIQ

TradingView

Marksans Pharma Share Key Metrics

Volume

11.00 L

Market Cap

10839.94 CR

LTQ@LTP

7@233.37

ATP

235.8 Var Margin

21.97 %

Circuit Range

191.32-286.96

Delivery %

0 %

Value

25.94 CR

ASM/GSM

No

Market Lot

1

Summary

5 Jun, 2026 | 11:47 को, Marksans Pharma का शेयर प्राइस आज ₹233.37 पर है, जो दिन के लिए 5.77% की -2.41 दर्शाता है। स्टॉक की इंट्राडे मूवमेंट ₹230.50 और ₹244.42 के बीच रही है, जबकि 52‑सप्ताह के आधार पर यह ₹155.00 से ₹270.70 तक रही है। ट्रेडिंग गतिविधि के मामले में, Marksans Pharma ने 1100282 शेयरों का वॉल्यूम रिकॉर्ड किया है, जिसका मार्केट कैपिटलाइज़ेशन ₹453288438 है। स्टॉक की एवरेज ट्रेडेड प्राइस ₹23580 है, जबकि लास्ट ट्रेडेड क्वांटिटी एट लास्ट ट्रेडेड प्राइस (LTQ@LTP) 7,23337 रही। यह स्टॉक ₹191.32-286.96 की सर्किट रेंज में ट्रेड करता है, और आज का कारोबार मूल्य ₹25.94 CR है। दिन के लिए डिलीवरी परसेंटेज % रही। इसके अतिरिक्त, Marksans Pharma वर्तमान में No फ्रेमवर्क के तहत आता है और 1 के मार्केट लॉट साइज़ में ट्रेड करता

Marksans Pharma Fundamentals

P/E Ratio

26.28

P/B Ratio

3.63

Div. Yield

0.37

Sector P/E

68.86

Sector P/B

2.96

Sec. Div. Yield

0.54

Marksans Pharma Resistance and Support

Pivot 240.17

Resistance

First Resistance

242.29

Second Resistance

245.43

Third Resistance

247.55

Support

First Support

237.03

Second Support

234.91

Third Support

231.77

Marksans Pharma Shareholding Pattern

2016-17
2018-19
2019-20
2020-21
2021-22
2022-23
2023-24
2024-25
2025-26
2026-27

Total Promoters

Segment

Percent

Total Promoters

43.87%

Mutual Fund

4.66%

Insurance

0%

Foreign Institutional Investors

16.76%

Domestic Institutional Investors

1.91%

Retail

32.79%

Others

0.01%

Total Promoters

MAR '26

43.87%

Marksans Pharma Corporate Actions

Date	Agenda
2026-05-26	Audited Results & Final Dividend
2026-02-05	Quarterly Results

Marksans Pharma News

Marksans Pharma Limited

Marksans Pharma acquired QliniQ B.V., a Netherlands-based distributor of medical devices and pharmaceutical products, for Euro 7.5 million (Rs. 82.98 crores). This acquisition will bolster Marksans' presence and leverage QliniQ's sales infrastructure in European markets.

Jun 02 2026 00:34:46

Marksans Pharma Limited

Marksans Pharma Ltd acquired 100% of Netherlands-based QliniQ B.V. for €7.5 million. This acquisition strengthens Marksans' presence in regulated European markets with QliniQ's profitable niche pharmaceutical and medical device portfolio.

Jun 01 2026 09:01:05

Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Marksans Pharma acquired 100% of Netherlands-based QliniQ B.V. for €7.5 million. This acquisition strengthens its presence in regulated European markets and provides direct access to the Dutch healthcare market.

Jun 01 2026 08:57:48

Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Marksans Pharma uploaded the audio recording of its Q4 FY26 investor/analyst conference call. The recording, covering the financial results discussed on May 27, 2026, is now available on the company's website for investor review.

May 27 2026 18:52:29

Marksans Pharma Ltd - 524404 - Corporate Action-Board approves Dividend

Marksans Pharma Board recommended a final dividend of ₹0.90 per equity share for FY2025-26. This 90% dividend is subject to shareholder approval at the AGM, with payout scheduled within 30 days post-AGM.

May 26 2026 13:34:34

Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Marksans Pharma announced strong FY26 results with total income reaching a historic high of Rs.3,033 crore, a 12.8% YoY increase. Net profit for the year also surged by 9.8% YoY to Rs.420 crore, reflecting robust performance and strategic growth initiatives across markets.

May 26 2026 13:30:37

Marksans Pharma Q4 Results: Stock jumps 12% after profit surges, margin expands

Marksans Pharma reported a robust financial performance for Q4 FY26, with consolidated net profit surging by 63.35% year-on-year to ₹149.03 crore. Revenue from operations grew by 20.8% to ₹856.11 crore, accompanied by a significant expansion in the EBITDA margin to 22.8%. The board also recommended a final dividend of ₹0.90 per share for FY26.

May 26 2026 13:26:11

Marksans Pharma Ltd - 524404 - Board Meeting Outcome for Outcome Of Board Meeting Held On 26 May, 2026

Marksans Pharma reported FY26 cons. revenue of ₹29,509.38 mn and PAT of ₹4,200.64 mn. The board also recommended a final dividend of ₹0.90 per share for FY26.

May 26 2026 12:54:51

Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Marksans Pharma has scheduled an earnings conference call for May 27, 2026, at 4:30 PM IST. The call will discuss the company's audited financial results for the quarter and year ended March 31, 2026.

May 19 2026 12:43:26

Marksans Pharma Ltd - 524404 - Board Meeting Intimation for Approval Of Audited Standalone And Consolidated Financial Results And To Consider Recommendation Of Dividend If Any, For The Financial Year Ended March 31, 2026

Marksans Pharma will convene a board meeting on May 26, 2026. The agenda includes the consideration and approval of audited financial results for the quarter and year ended March 31, 2026, and a recommendation for dividend.

May 12 2026 15:05:20

Name	Position
Harshavardhan Panigrahi	Company Secretary & Compliance Officer
Mark Saldanha	Chairman & Managing Director

Marksans Pharma Similar Stocks

Concord Biotech Ltd.

1221.00

-17.20 (1.39%)

Alivus Life Sciences Ltd.

1043.60

7.80 (0.75%)

Park Medi World Ltd.

284.90

-1.00 (0.35%)

Sanofi Consumer Healthcare India Ltd.

4759.60

57.00 (1.21%)

Metropolis Healthcare Ltd.

544.70

0.55 (0.10%)

Viyash Scientific Ltd.

256.60

7.45 (2.99%)

CORONA Remedies Ltd.

1723.80

22.50 (1.32%)

Shilpa Medicare Ltd.

537.50

11.70 (2.23%)

Strides Pharma Science Ltd.

1043.10

15.90 (1.55%)

Healthcare Global Enterprises Ltd.

636.10

-3.85 (0.60%)

Marksans Pharma FAQs

Marksans Pharma शेयर का खरीद मूल्य 233.37 है। लाइव प्राइस और तत्काल ट्रेडिंग के लिए, आप अपने चॉइस ट्रेडिंग खाते में लॉगिन कर सकते हैं या चॉइस के साथ मुक्त डीमैट खाता खोल सकते हैं।

Marksans Pharma शेयर खरीदने के लिए अपने चॉइस ट्रेडिंग खाते में लॉगिन करें, या चॉइस डीमैट खाता खोल, फिर फंड जोड़ें, कंपनी का नाम खोजें, अपना ऑर्डर टाइप चुनें और ट्रेड प्लेस करें।

Marksans Pharma शेयर का प्राइस-टू-अर्निंग्स (पी/ई) रेशियो 26.28 है। आप सापेक्ष मूल्यांकन के लिए इसकी तुलना सेक्टर के औसत से कर सकते हैं।

Marksans Pharma शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 3.63 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Marksans Pharma शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 2.96 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Marksans Pharma का मार्केट कैप 10839.94 CR है। यह कंपनी के आकार की श्रेणी और ट्रेडिंग लिक्विडिटी को दर्शाता है।

Marksans Pharma शेयर का 52 सप्ताह का उच्चतम और न्यूनतम मूल्य 270.70 और 155.00 है। ये मूल्य मूल्य सीमाएं, ट्रेडिंग रेंज, अस्थिरता, संभावित सपोर्ट/रेजिस्टेंस और मूल्य गति को दर्शाते हैं।